Investigation Overview
May 19, 2015 (Update) - On May 4, 2015, a news reports stated that AcelRx Pharmaceuticals Inc said a division of the FDA had rejected the company's request for a meeting to discuss the need for an additional trial of its pain drug device, Zalvizo. Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) declined on May 13, 2015 to as low as $2.96 per share. March 16, 2015, (Update) - On Ma...
You must register (for free) or login to view the entire investigation.